Precigen (NASDAQ:PGEN) Shares Up 5.2% – Should You Buy?

Precigen, Inc. (NASDAQ:PGEN) shares rose 5.2% during mid-day trading on Tuesday . The company traded as high as $5.09 and last traded at $5.1860. Approximately 640,574 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 3,493,187 shares. The stock had previously closed at $4.93.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PGEN. Wall Street Zen cut Precigen from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Zacks Research lowered shares of Precigen from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd. Finally, HC Wainwright raised their price target on Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a research note on Friday, November 14th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Precigen presently has an average rating of “Hold” and an average target price of $8.50.

Precigen Price Performance

The firm has a market capitalization of $1.60 billion, a PE ratio of -3.24 and a beta of 1.07. The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22. The company has a fifty day moving average price of $4.42 and a two-hundred day moving average price of $3.93.

Insider Activity at Precigen

In other news, Director Randal J. Kirk sold 1,900,036 shares of Precigen stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.18, for a total value of $7,942,150.48. Following the transaction, the director directly owned 341,189 shares of the company’s stock, valued at $1,426,170.02. The trade was a 84.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 47.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Patient Capital Management LLC lifted its position in Precigen by 62.6% during the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock worth $87,056,000 after acquiring an additional 10,192,107 shares during the period. State Street Corp grew its position in Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after buying an additional 6,335,033 shares during the period. Geode Capital Management LLC grew its holdings in shares of Precigen by 15.9% in the 4th quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock worth $18,653,000 after acquiring an additional 613,340 shares during the period. Occam Crest Management LP increased its position in shares of Precigen by 29.6% in the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after buying an additional 799,339 shares in the last quarter. Finally, SymBiosis Capital Partners LLC purchased a new position in Precigen during the 4th quarter valued at about $12,540,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.